Correction

Table I.

Patient́s Characteristics, Status Before and Response to DC Vaccination

				Metastases at study entry
				Regional			Distant
Patientcode	Sexage	Center	Previoustherapy	Skin	LN	Skin	LN	Lung	Liver	Skeleton	Others	Clinicalresponse
Fully evaluable patients (five vaccinations)
02	m-48	E	S, ILP, IT, RT, CIT	-	-	-	-	D/5	-	-	Pancreas 2/35	CR
05	f-77	E	S, ILP, IT, RT, CT	6/34	-	-	-	-	-	-		SD
08	f-64	E	S, IT, CIT, CT	-	-	1/3	1/4	-	2/80	-	Muscle 1/60	OP
10	m-41	E	S, IT	-	2/13	-	-	-	-	-		SD
12	f-65	E	S, CT	-	-	-	1/15	D/10	-	-		SD
14	m-58	E	S, IT, CT	-	-	-	-	D/25	-	-		OP
15	f-35	E	S, CIT	-	2/20	-	-	-	-	-		SD
16	m-63	I	S	-	2/30	-	1/25	-	-	1/20		OP
17	f-60	I	S, CIT	-	-	D/10	3/26	1/3	-		Kidney 2/15, suprarenal 2/60	OP
18	m-77	I	S	-	-	-	-	3/30	1/14	3/60		OP
19	m-70	E	S, IT	-	-	-	-	9/25	-	2/25		OP
20	m-64	E	S, IT, RT	D (>50)/5	-	D/5	-	-	-	-		SD
21	m-59	E	S, IT	-	2/9	-	-	-	-	-		SD
23	f-36	E	S, IT, CT	3/14	-	-	-	-	-	-	Intestine D^{^a}	SD
27	f-44	I	S, IT	-	-	-	1/51	1/16	-	-		SD
28	m-55	E	S, CIT, ILP	-	2/6	-	3/30	-	-	-		OP
Not fully evaluable patients (less than five vaccinations)
01	f-29	E	CIT	-	-	-	D/8	-	1/5	-	Spleen 3/35 peritoneum D muscle 2/30	^†
03	m-59	E	S, IT, CT	1/70	D/15	-	-	-	-	-	Sinus cavernosus infiltration; bone	^†
04	f-55	E	S, IT, CT	-		-	D/30	-	-	-		OP
07	f-48	I	S, CIT, RT	-	1/20	-	D/50	-	-	-		OP
09	m-57	E	S, CIT	1/11	-	-	D	-	D	-	Pancreas, duodenum, gastric D	OP
11	f-71	E	S	D (>50)/5	-	-		-	-	-		OP
13	f-49	I	S	-	-	-	D/35	-	-	-		OP
24	f-37	I	S, CT, IT, RT	-	-	-	1/45	1/20	-	-		OP

				Metastases at study entry
				Regional			Distant
Patientcode	Sexage	Center	Previoustherapy	Skin	LN	Skin	LN	Lung	Liver	Skeleton	Others	Clinicalresponse
Fully evaluable patients (five vaccinations)
02	m-48	E	S, ILP, IT, RT, CIT	-	-	-	-	D/5	-	-	Pancreas 2/35	CR
05	f-77	E	S, ILP, IT, RT, CT	6/34	-	-	-	-	-	-		SD
08	f-64	E	S, IT, CIT, CT	-	-	1/3	1/4	-	2/80	-	Muscle 1/60	OP
10	m-41	E	S, IT	-	2/13	-	-	-	-	-		SD
12	f-65	E	S, CT	-	-	-	1/15	D/10	-	-		SD
14	m-58	E	S, IT, CT	-	-	-	-	D/25	-	-		OP
15	f-35	E	S, CIT	-	2/20	-	-	-	-	-		SD
16	m-63	I	S	-	2/30	-	1/25	-	-	1/20		OP
17	f-60	I	S, CIT	-	-	D/10	3/26	1/3	-		Kidney 2/15, suprarenal 2/60	OP
18	m-77	I	S	-	-	-	-	3/30	1/14	3/60		OP
19	m-70	E	S, IT	-	-	-	-	9/25	-	2/25		OP
20	m-64	E	S, IT, RT	D (>50)/5	-	D/5	-	-	-	-		SD
21	m-59	E	S, IT	-	2/9	-	-	-	-	-		SD
23	f-36	E	S, IT, CT	3/14	-	-	-	-	-	-	Intestine D^{^a}	SD
27	f-44	I	S, IT	-	-	-	1/51	1/16	-	-		SD
28	m-55	E	S, CIT, ILP	-	2/6	-	3/30	-	-	-		OP
Not fully evaluable patients (less than five vaccinations)
01	f-29	E	CIT	-	-	-	D/8	-	1/5	-	Spleen 3/35 peritoneum D muscle 2/30	^†
03	m-59	E	S, IT, CT	1/70	D/15	-	-	-	-	-	Sinus cavernosus infiltration; bone	^†
04	f-55	E	S, IT, CT	-		-	D/30	-	-	-		OP
07	f-48	I	S, CIT, RT	-	1/20	-	D/50	-	-	-		OP
09	m-57	E	S, CIT	1/11	-	-	D	-	D	-	Pancreas, duodenum, gastric D	OP
11	f-71	E	S	D (>50)/5	-	-		-	-	-		OP
13	f-49	I	S	-	-	-	D/35	-	-	-		OP
24	f-37	I	S, CT, IT, RT	-	-	-	1/45	1/20	-	-		OP

Deceased.

Surgically removed prior to therapy.

Treatment Centers: E, Erlangen; I, Innsbruck.

Pretreatment therapy: IT, immunotherapy; C(I)T, chemo(immuno)therapy; S, surgery.

RT, radiotherapy; ILP, isolated limb perfusion.

Metastases at study entry: the number and diameter of the largest metastases present at study entry are listed (number/diameter in mm); D, diffuse.

Clinical Response: CR, complete regression; OP, overall progression; SD, stable disease.